Survey of Practices Regarding the Use of Taurolidine Lock Solutions in Patients With Insertion of a Peripherally Inserted Central Catheter (PICC) in a Vascular Access Unit
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 45
- 主要终点
- To characterize, through an assessment of current practices, the administration of taurolidine lock solutions as prescribed for patients who have undergone PICC implantation in the Vascular Access Unit as part of parenteral nutrition therapy.
研究概览
简要总结
The primary objective of this study is to describe current practices regarding the administration of taurolidine lock solutions in relation to medical prescriptions for patients who have undergone peripherally inserted central catheter (PICC) implantation in the Vascular Access Unit as part of parenteral nutrition therapy. Our underlying hypothesis is that the use of taurolidine lock solutions may deviate from current recommendations, particularly with respect to administration procedures.
This study will allow us to characterize the use of taurolidine lock solutions in relation to medical prescriptions, identify potential deviations from recommended practices, and document any associated adverse events. It will also enable follow-up of PICC outcomes at 8 and 30 days after implantation in the Vascular Access Unit, whereas current follow-up is performed only at 8 days post-insertion.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who has undergone PICC placement in the vascular access unit with an indication for parenteral nutrition supplementation.
- •Patient not opposed to participating in this research.
排除标准
- •Patient not speaking French
- •Patient under guardianship or conservatorship
- •Patient with major neurocognitive disorders
- •Patient with severe hearing impairment
- •Patient who do not have a telephone
结局指标
主要结局
To characterize, through an assessment of current practices, the administration of taurolidine lock solutions as prescribed for patients who have undergone PICC implantation in the Vascular Access Unit as part of parenteral nutrition therapy.
时间窗: Eight and thirty days after PICC placement in the Vascular Access Unit
Proportion of patients with a prescription for a taurolidine lock solution who actually receive administrations of the prescribed lock solution (concordance between prescribed and administered product). Proportion of patients for whom lock solutions are administered in accordance with the manufacturer's instructions for use; compliant administration is defined as the nurse performing all recommended steps for applying the lock solution at the end of each parenteral nutrition infusion. Proportion of patients for whom lock solutions are withdrawn in accordance with the manufacturer's instructions for use (lock solutions aspirated before catheter use). Proportion of patients for whom lock solutions are disposed of in accordance with regulations for biological-hazard waste.
次要结局
- Describe the elements related to PICC placement.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Characterize the functional status of the PICC over time.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Describe complications related to PICC placement.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Describe nurses' perceptions of their own knowledge regarding the use of taurolidine lock solutions.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Describe the supply chain for taurolidine lock solutions.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Describe the medical care provided by home service providers for patients receiving a PICC placement for parenteral nutrition supplementation.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Describe the causes of premature PICC removal.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Describe adverse events related to the use of taurolidine lock solutions.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Describe the difficulties encountered by healthcare professionals when using taurolidine lock solutions.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Describe the information sources used by healthcare professionals regarding taurolidine lock solutions.(Eight and thirty days after PICC placement in the Vascular Access Unit.)
- Characterize the use of device vigilance in the event of adverse events related to taurolidine lock solutions.(Eight and thirty days after PICC placement in the Vascular Access Unit.)